Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKinsey
Express Scripts
Novartis
Teva
Accenture
Federal Trade Commission
Julphar
Medtronic

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,060,499

« Back to Dashboard

Which drugs does patent 6,060,499 protect, and when does it expire?

Patent 6,060,499 protects TREXIMET and is included in one NDA.

Protection for TREXIMET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixteen patent family members in eleven countries.
Summary for Patent: 6,060,499
Title: Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs
Abstract:This invention comprises a method of treating migraine in a human comprising co-timely administering of a therapeutically effective amount of a 5-HT agonist coordinated with a therapeutically effective amount of an analgesic, particularly a long-acting NSAID, and in some instances, doses below those ordinarily considered as minimum effective doses as to one or both 5-HT agonist and long-acting NSAID. Dosage forms are also included herein.
Inventor(s): Plachetka; John R. (Chapel Hill, NC)
Assignee: Pozen, Inc. (Chapel Hill, NC)
Application Number:09/151,912
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 6,060,499

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pernix Ireland Ltd TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-002 May 14, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pernix Ireland Ltd TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-001 Apr 15, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,060,499

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,872,145 Formulation of 5-HT agonist and NSAID for treatment of migraine ➤ Sign Up
6,586,458 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs ➤ Sign Up
8,022,095 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,060,499

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 957914 ➤ Sign Up
Japan 2005325143 ➤ Sign Up
Japan 2002255855 ➤ Sign Up
Japan 3712420 ➤ Sign Up
Japan 2000506541 ➤ Sign Up
Hong Kong 1023517 ➤ Sign Up
Spain 2234025 ➤ Sign Up
European Patent Office 0957914 ➤ Sign Up
Denmark 0957914 ➤ Sign Up
Germany 69732189 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Argus Health
Chubb
Moodys
Citi
Healthtrust
Chinese Patent Office
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot